Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study

BACKGROUND: Ipragliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubules. SGLT2 inhibitors are expected to be effective in patients with insulin resistance and obesity, but it is important to select treatment according to pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Iemitsu, Kotaro, Iizuka, Takashi, Takihata, Masahiro, Takai, Masahiko, Nakajima, Shigeru, Minami, Nobuaki, Umezawa, Shinichi, Kanamori, Akira, Takeda, Hiroshi, Kawata, Takehiro, Ito, Shogo, Kikuchi, Taisuke, Amemiya, Hikaru, Kaneshiro, Mizuki, Mokubo, Atsuko, Takuma, Tetsuro, Machimura, Hideo, Tanaka, Keiji, Asakura, Taro, Kubota, Akira, Aoyagi, Sachio, Hoshino, Kazuhiko, Ishikawa, Masashi, Obana, Mitsuo, Sasai, Nobuo, Kaneshige, Hideaki, Miyakawa, Masaaki, Tanaka, Yasushi, Terauchi, Yasuo, Matsuba, Ikuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817576/
https://www.ncbi.nlm.nih.gov/pubmed/27081422
http://dx.doi.org/10.14740/jocmr2492w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817576/
https://www.ncbi.nlm.nih.gov/pubmed/27081422
http://dx.doi.org/10.14740/jocmr2492w

Ejemplares similares